At a glance
- Originator Unknown
- Developer Zydus-Cadila
- Class Antihyperlipidaemics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 26 May 2000 No-Development-Reported for Hyperlipidaemia in India (Unknown route)
- 31 Dec 1994 Phase-I clinical trials for Hyperlipidaemia in India (Unknown route)